Dr. Lucas Moreno, head of the Pediatric Oncohematology Service of Vall d'Hebron, is the leader of the clinical trial BEACON-Neuroblastoma, who has shown promising results in the treatment with the bevacizumab drug for patients with relapse or resistant neuroblastoma treatment. This is one of the most frequent and aggressive pediatric tumors.Neuroblastoma is one of the most common cancers in children under five and represents half of cancers in infants. This type of tumor is formed from embryo cells formed by the sympathetic ganglia and can have a very varied clinical presentation. In the case of high-risk neuroblastomas, those in which the disease is disseminated with metastases or that have a gene called MYCN, chemotherapy, surgery, radiotherapy, bone marrow transplantation and immunotherapy must be combined and, despite this treatment intensive, it is still one of the first causes of cancer mortality in children.The clinical trial led by Dr. Lucas Moreno, promoted by the University of Birmingham, has concluded that adding bevacizumab to chemotherapy treatment can reduce the size of these tumors. This new medication brakes the arrival of blood to the tumor by attacking the blood vessels that these form. It is the largest randomized study performed in relapse or refractory neuroblastoma, performed with 160 patients between 1 and 21 years. "The clinical trial points out that incorporating bevacizumab to the treatment of neuroblastoma relapse improves the proportion of patients who respond to the treatment, as it causes tumors to grow less," says Dr. Lucas Moreno. The study will also evaluate whether bevacizumab treatment added to chemotherapy improves patient survival, results that will be available in 2020, and will help define how these patients should be treated in the near future.